Outcomes of the 335 umbilical cord blood transplant recipients by preparative regimen and administration of ATG
. | Myeloablative . | . | . | Nonmyeloablative . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome . | Without ATG (95% CI) . | With ATG (95% CI) . | P . | Without ATG (95% CI) . | With ATG (95% CI) . | P . | ||||
| No. of patients | 66 | 174 | 65 | 30 | ||||||
| Grade II-IV acute GVHD, % | 58 (45-71) | 34 (27-41) | <.01 | 63 (49-77) | 37 (19-55) | .04 | ||||
| Extensive chronic GVHD at 1 y, % | 20 (10-30) | 8 (4-12) | <.01 | 28 (16-40) | 21 (5-37) | .92 | ||||
| Primary neutrophil engraftment, % | 97 (93-100) | 92 (88-96) | .17* | 92 (86-98) | 94 (84-100) | .50* | ||||
| Survival at 2 y, % | 60 (56-76) | 52 (44-60) | .58 | 46 (32-60) | 45 (25-65) | .14 | ||||
. | Myeloablative . | . | . | Nonmyeloablative . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome . | Without ATG (95% CI) . | With ATG (95% CI) . | P . | Without ATG (95% CI) . | With ATG (95% CI) . | P . | ||||
| No. of patients | 66 | 174 | 65 | 30 | ||||||
| Grade II-IV acute GVHD, % | 58 (45-71) | 34 (27-41) | <.01 | 63 (49-77) | 37 (19-55) | .04 | ||||
| Extensive chronic GVHD at 1 y, % | 20 (10-30) | 8 (4-12) | <.01 | 28 (16-40) | 21 (5-37) | .92 | ||||
| Primary neutrophil engraftment, % | 97 (93-100) | 92 (88-96) | .17* | 92 (86-98) | 94 (84-100) | .50* | ||||
| Survival at 2 y, % | 60 (56-76) | 52 (44-60) | .58 | 46 (32-60) | 45 (25-65) | .14 | ||||
ATG indicates antithymocyte globulin; CI, confidence interval; and GVHD, graft-versus-host disease
Comparison of proportions at day 42 after UCB transplantation